On May 12, 2025 IN8bio, Inc. (Nasdaq: INAB), a clinical-stage biopharmaceutical company developing innovative gamma-delta (γδ) T cell therapies for cancer and autoimmune diseases, reported new data on its proprietary γδ T manufacturing program (Press release, In8bio, MAY 12, 2025, View Source [SID1234652884]). The oral presentation shared exciting updates about its unique manufacturing processes, including deep analytics, genomics and repertoire analysis, presented at the International Society for Cell & Gene Therapy (ISCT) 2025 Annual Meeting. The data, which earned IN8bio the prestigious Host Region (U.S. East) Abstract Award, as presented by Bruce Levine, PhD, ISCT Past President and a member of IN8bio’s Scientific Advisory Board. The award is a competitive recognition for scientific excellence and demonstrates how IN8bio’s technology and know-how creates consistent, powerful cellular therapies.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
The oral presentation highlights how IN8bio’s DeltEx Allo manufacturing process consistently induces donor derived T cells to express γδ T cell receptors (TCRs) and genes, associated with increased cancer cytotoxicity. Gene expression profiling confirmed a highly potent product across multiple manufacturing batches.
"Manufacturing abilities are paramount to the successful and safe development of cellular therapies. From process development through clinical manufacturing and product characterization, IN8bio uniquely maintains hands-on control of all steps in the process. These data and the Abstract Award further establish IN8bio as a leader in clinical grade γδ T cell manufacturing," said Kate Rochlin, Chief Operating Officer of IN8bio. "The power of our platform is our ability to consistently produce robust cell products with signatures associated with cytotoxicity, immune activation, and tissue trafficking. Our knowledge and know-how are key differentiators as we efficiently scale manufacturing to support our clinical trials and potential future commercialization."
Key Findings from the INB-100 Study Presented at ISCT:
Manufacturing-Driven TCR Reprogramming: All analyzed clinical batches showed a clear and consistent shift from αβ-TCR to γδ-TCR dominance, with enrichment of Vγ9 clones. This shift occurred independent of donor starting material, indicating the process—not the donor—drives final TCR composition.
Uniform Potency Markers Across Donors: All manufactured clinical products showed high expression levels of genes linked to increased cancer killing, immune activation, and tumor seeking migration.
Durable Remissions in AML Patients: All 10 patients in the initial cohort remained relapse-free for more than one year, with a median overall survival of 23.3 months as of January 2024.
These results highlight the strength and reproducibility of IN8bio’s cell therapy manufacturing processes. These products were administered clinically in the INB-100 clinical trial, which has demonstrated durable long-term remissions in adult AML patients with high-risk, complex disease characteristics. Further, long term expansion and persistence of the γδ T cells have been observed in these patients through 1 year, a first for an allogeneic cellular therapy product. IN8bio‘s manufacturing program has been automated, enabling rapid and reproducible production of cryopreserved cell therapy doses. The INB-100 trial continues to enroll an expansion cohort at the recommended Phase 2 dose (RP2D).